Stock Detail
Videos
Cadrenal Therapeutics (CVKD) Fireside Chat
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) is a biopharmaceutical company focused on developing therapies for patients with cardiovascular diseases and unmet medical needs. The company is advancing programs intended to address critical treatment gaps while improving...
Cadrenal Therapeutics (CVKD) Fireside Chat
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is developing differentiated products designed to bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations. This fireside chat was recorded during the Lytham...
Cadrenal Therapeutics (CVKD) Company Webcast
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing transformative therapeutics to address limitations of current anticoagulation therapy. This company webcast was recorded during the Lytham Partners Fall 2025 Investor Conference.
News
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham...
Cadrenal Therapeutics to Participate in H.C. Wainwright’s 28th Annual Global Investment Conference
PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham...
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated $2 Billion in Peak Annual Revenue Opportunity...